Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user experienced temple recession, shedding, and acne while on 0.5mg dutasteride, 1.25mg finasteride every other day, and 5mg oral minoxidil daily. They are considering switching treatments due to worsening symptoms and are contemplating using a topical anti-androgen like RU58841.

A 19-year-old is distressed about his 17-year-old autistic brother's hair loss, projecting his own insecurities despite being on finasteride and dutasteride. Replies suggest the brother might not care about balding, and the poster should address his own issues.

The user has been using finasteride and oral minoxidil for two years without improvement in diffuse thinning and is considering switching to dutasteride and getting a scalp biopsy. Suggestions include treating subclinical hypothyroidism, trying PRP therapy, and checking for autoimmune issues.

The user experienced hair thinning, possibly due to long COVID and prediabetes, and saw regrowth after dietary changes and using biotin shampoo. They are taking vitamins and noticed significant hair regrowth, especially at the widow's peak.

Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.

Breezula results are awaited, but no updates have been posted. Users are uncertain about its promise.

The user is experiencing breast tissue growth from taking dutasteride and minoxidil, and is considering reducing the dosage or stopping the medication. Suggestions include seeing an endocrinologist, using Raloxifene or Arimidex, and considering topical treatments or surgery if necessary.

High estradiol levels may contribute to erectile dysfunction (ED) and can be addressed with lifestyle changes or medication. It's important to consult a medical professional for treatment options.

Oral minoxidil can cause facial bloating, leading to a puffy appearance. Some users report improvement after stopping the medication.

Oral minoxidil can cause side effects like shortness of breath and constipation, which may be reduced by taking it in the morning. Some users experience no side effects, while others switch to topical treatments or adjust their dosage and timing to manage symptoms.

The conversation is about purchasing Breezula, a hair loss treatment. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

The user experiences an itchy scalp and finds relief using shampoo and Zyrtec, which helps with inflammation. They are unsure if the issue is related to histamines or seborrheic dermatitis.

Switching from topical to oral minoxidil caused acne breakouts, leading the user to revert to topical use. Finasteride was also used, but acne was suspected to be linked to oral minoxidil.

Breezula shows promising results for hair loss, with one trial showing a 539% improvement and another 168%, but lacks combination data with treatments like minoxidil or dutasteride. Its mechanism differs from finasteride, potentially offering fewer side effects by blocking receptors locally at the follicle.

Breezula (cb-03-01) and kx-826 are discussed as hair loss treatments. Kx-826 is available on Kintor's website, while Breezula is available on the grey market.

The conversation discusses liver issues potentially linked to long-term use of finasteride and dutasteride, with users sharing similar experiences of elevated liver enzymes, high cholesterol, and other health concerns. The consensus suggests stopping the medication and consulting a healthcare professional for proper diagnosis and treatment.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The user experienced heart palpitations after starting oral minoxidil and wonders if it's due to increased cardio activities or the medication. Other users suggest it might be a side effect of minoxidil, with some sharing similar experiences, and recommend consulting a doctor.

The conversation is about baricitinib, a medicine that can help with hair loss, and why it isn't more popular or widely discussed. No specific experiences with the treatment were shared.

A user switched from finasteride and topical minoxidil to dutasteride and oral minoxidil, but experienced worsening hair loss and thinning. Suggestions included returning to finasteride, adding finasteride to the current regimen, or considering other factors like genetics or additional causes of hair loss.

The user experienced scalp burning and diffuse hair shedding after surgery, with symptoms worsening due to factors like weather changes and stress. They tried minoxidil and finasteride but stopped due to side effects, and found some relief with corticosteroid scalp treatments while correcting vitamin deficiencies.

Breezula's effectiveness may depend on the vehicle used for its application, with concerns about the grey market version's formulation. Phase 3 results are promising, but skepticism remains about the grey market product's authenticity and effectiveness.

Breezula protects hair follicles from both testosterone and DHT, unlike finasteride, which only protects against DHT. This could potentially lead to significant hair regrowth, similar to results seen in transgender individuals using hormone blockers.

The user experienced anxiety and heart pounding from oral minoxidil, despite its effectiveness, and switched back to topical minoxidil. After managing anxiety, they found oral minoxidil more effective, but side effects differ for each person.

Bicalutamide blocks androgen receptors, preventing testosterone and DHT from binding, which can help with hair loss but may cause feminization. It is not recommended for those who do not want feminization effects.

Beta blockers may cause hair thinning as a side effect. The user is concerned about this and seeks others' experiences with hair loss while using beta blockers.